1,586
Views
10
CrossRef citations to date
0
Altmetric
Commentary

An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein

ORCID Icon & ORCID Icon
Pages 92-97 | Received 11 Apr 2020, Accepted 10 Jun 2020, Published online: 14 Jul 2020

Figures & data

Figure 1. The spike protein of the coronavirus binds to ACE2 on target cells (include lung and gastrointestinal tissues in the human body) leading to cell entry. The sACE2-anti-CD16 VHH bi-specific molecule not only blocks SARS-CoV-2 from infecting cells but also mediates ADCC by NK cells. Anti-CD16 VHH fused to soluble ACE2 would prolonged the construct circulation half-life in the body

Figure 1. The spike protein of the coronavirus binds to ACE2 on target cells (include lung and gastrointestinal tissues in the human body) leading to cell entry. The sACE2-anti-CD16 VHH bi-specific molecule not only blocks SARS-CoV-2 from infecting cells but also mediates ADCC by NK cells. Anti-CD16 VHH fused to soluble ACE2 would prolonged the construct circulation half-life in the body

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.